AHR and metabolic dysfunction-associated steatotic liver disease: The role of AhR in NAFLD is therefore intricate and targeting AhR or its signaling pathway components for future drug development must take into consideration the characteristics of the ligand including binding affinity and duration of interaction with AhR, tissue/cell-specific activity of ligand, coactivators and corepressors interacting with AhR in response to ligand binding, epigenetic modifications, modulation of chromatin structure and cross-talk of AhR with other signaling pathways.